In an industry where fewer than 8% of drug candidates entering Phase I clinical trials ever reach regulatory approval, and roughly half of those that launch fail to recover their development costs, biopharma operates as a failure-dominated ecosystem. Yet, as Dr. David H. Crean convincingly demonstrates in Dual Fluency: Bridging Science, Capital, and Governance in Life Sciences, the vast majority of promising therapeutics die in the “Translation Gap.” In short, the horror dilemma here is the quiet, organizational chasm where scientific reality fails to convert into capital strategy, deal structures, and rigorous governance decisions.
Crean’s work arrives at a critical tipping point for the life sciences sector. He argues that historical margins that once allowed a brilliant scientist-CEO to rely blindly on financial advisors or helped a finance-native executive to gloss over biological nuances have completely vanished or become outdated in this digital age. This book asks leaders to adopt Dual Fluency, which dismantles this siloing and offers an urgent, highly practical architecture for biopharma leadership that can be achieved via its systematic approach to demystifying the three fundamental translations required to bring a molecule from benchtop to market:
- Data to Capital: Institutional investors do not underwrite raw scientific enthusiasm; they price probability-weighted risk and return. Crean provides clear frameworks for converting preclinical assays, biomarker data, and patient stratification metrics into structured valuation trees that demonstrate real biological and regulatory derisking at each financing stage.
- Discovery to Deal: Securing corporate partnerships, pharma licensing agreements, or non-dilutive royalty financing requires deal terms that reflect clinical realities. Dual Fluency outlines how poorly structured milestone triggers and governance rights can lock core assets in regulatory limbo or cause catastrophic dilution during pipeline pivots.
- Bench to Boardroom: Transitioning from drug discovery to corporate stewardship demands a profound mindset shift from “What else can this asset do?” to “How do we deploy finite capital for maximum risk-adjusted impact?” The book offers a blueprint for boardrooms to exercise disciplined fiduciary control, including knowing precisely when to kill lagging programs early to protect cash runways.
What makes Dual Fluency especially timely is its sharp analysis of five converging industry forces: the rapid rise of AI-native biotech platforms, the fracture of traditional pharma business development models, the expanding complexity of modern capital stacks (from BARDA grants to royalty monetization), the rise of fractional C-suite leadership, and escalating investor expectations for boardroom governance.
Crean’s writing is direct, avoiding academic abstractions in favor of real-world deal dynamics, term-sheet pitfalls, and strategic negotiation tactics. While primarily written for pre-commercial scientist-founders whose translation gap is often the most consequential, the book is vital for business development leaders, CFOs, and venture investors.
Dual Fluency is an essential operational playbook for anyone stewarding high-stakes capital or groundbreaking science. By teaching leaders to hold both biological reality and financial discipline in view simultaneously, this practical book provides the blueprint needed to ensure transformative medicines don’t remain trapped in the lab but reach the patients waiting for them. If you are looking for innovation and transformative leadership in this competitive and contemporary world, this book has to be your next read.
